Seattle-based Accolade is set to go private again in a deal to be acquired by Transcarent that brings together two health benefits companies. Transcarent will acquire Accolade for $7.03 per share in cash, representing a total equity value of $621 million, and a premium of about 110% over Accolade’s closing stock price Tuesday.